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ScienceDirectFungi are ubiquitous transient or persistent human colonisers,
and form the mycobiome with shifts in niche specific
mycobiomes (dysbiosis) being associated with various
diseases. These complex interactions of fungal species with
the human host can be viewed as a spectrum of symbiotic
relationships (i.e. commensal, parasitic, mutualistic,
amensalistic). The host relevant outcome of the relationship is
the damage to benefit ratio, elegantly described in the damage
response framework. This review focuses on Candida albicans,
which is the most well studied human fungal symbiont
clinically and experimentally, its transition from commensalism
to parasitism within the human host, and the factors that
influence this relationship.
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Introduction
Fungi are ubiquitous within the environment. However,
only a few species are routinely found associated with
humans and are capable of causing disease. A handful of
these fungi are considered true pathogens, causing dis-
ease in healthy individuals (Histoplasma and Paracocci-
dioides), while the majority of fungi are often classified as
opportunistic pathogens (i.e. Candida and Cryptococcus),
causing disease primarily in immunosuppressed individ-
uals [1]. However, it is apparent that some opportunistic
fungal pathogens also cause disease in otherwise healthy
individuals (i.e. Candida vaginitis or Cryptococcus gattii
outbreaks) [2,3]. To understand and categorize the com-
plexity of these different interactions between host and
pathogen, Casadevall and Pirofski proposed the damageCurrent Opinion in Microbiology 2017, 40:58–64 response framework (DRF), which defines microbial vir-
ulence as a function of host damage [4]. Within this
framework, host damage (and therefore disease) can occur
at either end of the host immune response spectrum (i.e.
weakened or hyperactive immune defences). Along this
spectrum there is a continuum between pathogen-medi-
ated and host-mediated damage, which results in disease
only when damage impairs the normal function of the
host.
Host damage also varies as a function of time, with several
possible outcomes of host–pathogen interactions. For
example, as the amount of damage increases over time
and surpasses a threshold, disease ensues [4]. Fungal
pathogens that are able to exist within the host for
extended periods of time with limited damage lead to
other outcomes, including latency (Cryptococcus) or com-
mensalism. In addition, many fungal pathogens cause
chronic (long-term) infections, and therefore could also
be classified as symbionts, albeit with different host/
microbe damage to benefit ratios. The most well studied
fungal commensal is Candida albicans, which colonises the
oral, genital and gastrointestinal tracts, but can cause host
damage and disease in the context of weakened or uncon-
trolled immune responses. An environmental reservoir
of C. albicans has not yet been identified. Therefore,
C. albicans is considered an obligate commensal fungus.
This and its ability to fit within all six classes of the DRF
[5] have made C. albicans the model fungus for studying
the transition from commensal to pathogen and will be
the main focus of this review.
Symbiosis within the human ecosystem
Symbiosis is a type of long-term close biological relation-
ship between two or more species. These relationships
can be mutualistic (all organisms benefit), commensalistic
(one organism benefits without affecting the other), par-
asitic (one organism benefits at the expense of the other),
or amensalistic (one organism is inhibited or obliterated,
while the other is unaffected). For example, most host–
pathogen interactions are parasitic with the pathogen
causing damage to the host. However, as mentioned
above, periods of latency during an infection may be
classed as a commensal relationship as damage to the
host is minimal during this period. Interactions between
members of the microbiome may be described as amen-
salistic as the presence of some species prevent the
growth of others through nutrient depletion and the
secretion of chemical mediators. This is an important
factor as dysbiosis of the microbiome has been identifiedwww.sciencedirect.com
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Transition of C. albicans from commensal to parasite. During commensal growth C. albicans grows predominately as yeast and is tolerated by the
host, and does not activate innate immune responses. Periods of dysbiosis and immune suppression permit C. albicans to proliferate, induce
hyphal formation, and activate innate immune responses. At the vaginal mucosal, epithelial cells become sensitised resulting in hyperactivation of
innate immune responses and neutrophil influx. This non-protective hyperactivation of neutrophils results in damage to the vaginal mucosa and
symptomatic vaginal candidiasis.as a major contributor for several fungal infections (i.e.
vulvovaginal candidiasis, atopic dermatitis). Although
common for bacterial species, the idea of mutualistic
relationships between fungi and the human host is a
new concept as the potential benefit to the host of
harbouring fungi is still unknown (Figure 1).
Niche-specific fungal symbionts
Fungal symbionts vary in route of acquisition, niche/s
inhabited, and ultimately, the type of symbiotic relation-
ship formed. Some species are acquired at birth by direct
transmission, leading to colonization of the skin and
mucosal surfaces, while many fungal pathogens are ubiq-
uitous within the environment, leading to constant expo-
sure by oral or respiratory routes, as well as skin contact.
Most of these exposures are transient, due to clearance by
host immune responses or out competition for resources
by the microbiome. However, changes in immune status
or dysbiosis could lead to chronic colonisation and even-
tual host damage.
Mycobiome studies have been performed for most muco-
sal surfaces including the oral cavity [6], GI tract [7,8],www.sciencedirect.com vagina [9,10], lung [11,12], and skin [13,14]. Over 75 gen-
era of fungi have been identified in the oral cavity alone,
which can seed the respiratory or GI tract mycobiome.
The most common fungal species associated with the GI
tract are Candida, Saccharamyces and Cladosporium,
although DNA from more than 50 genera of fungi has
been detected. Stability and fluctuations in population
dynamics of the GI mycobiome is highly dependent on
diet and host immune status. For example, Saccharomyces
cerevisiae is commonly acquired from dietary sources and
is considered to be a harmless or transient commensal.
However, inflammatory bowel diseases [15] and some
autoimmune diseases [16,17] are associated with
increased levels of circulating S. cerevisiae antibodies
(ASCA), which recognise fungal cell wall components
[18]. Although it has been documented that C. albicans
is an immunogen for development of ASCA [19], dietary
S. cerevisiae can exacerbate symptoms in ASCA positive
IBD patients [20]. In this situation, S. cerevisiae may be
considered a parasitic symbiont. On the other end of the
spectrum, a related species, S. boulardii, is used clinically
as a probiotic treatment for gastroenteritis, acting as a
mutualistic symbiont [21].Current Opinion in Microbiology 2017, 40:58–64
60 Host-microbe interactions: fungiThe vaginal mucosa is colonised by a variety of fungi and
bacteria. Although Candida spp. are thought to be the
predominate fungal colonisers of the vaginal mucosa,
more recent microbiome studies have detected up to
20 genera of fungi in the vaginal niche, including Candida,
Aspergillus and Cladosporium [22]. In healthy women,
these fungal colonisers likely behave as commensal sym-
bionts. However, many host and environmental factors
including pregnancy, antibiotic usage and uncontrolled
diabetes influence the vaginal microbiota and can result
in dysbiosis and infection.
The dominant fungal commensal of the skin is Malassezia
spp. [23], a lipophilic genus that consists mostly of plant
pathogens. The lipid composition of the skin plays a role
in controlling fungal colonisation, with Malassezia globasa
being the predominate coloniser of the scalp and forehead
and Malassezia restricta colonising the back [24]. However,
Malassezia colonisation levels also correlate with a variety
of skin diseases including psoriasis, dandruff, atopic der-
matitis/eczema, seborrheic dermatitis, and pityriasis ver-
sicolor [25]. This suggests that above a certain threshold,
these commensals act as parasitic symbionts, possibly due
to increases in antigenic load. As evidence of this, it was
shown that M. sympodialis secretes allergen-loaded exo-
somes that induce pro-inflammatory responses [26].
Candida albicans: the ubiquitous fungal
symbiont
C. albicans is a commensal fungus of the oral, gastrointes-
tinal and genital tracts in up to 80% of healthy individuals.
Under specific host and environmental conditions,
C. albicans can transition from its commensal state to a
parasitic state causing mucosal (oral and vaginal candidi-
asis) and life-threatening systemic disease. The polymor-
phic nature of C. albicans is a key virulence factor playing
essential roles in the transition from commensalism
to parasitism [27]. Several yeast-like morphologies aid
C. albicans commensalism. For example, gastrointestin-
ally induced transition (GUT) cells promote commensal-
ism of C. albicans within the GI tract [28], grey cells enable
colonisation of the tongue [29] and opaque cells have
increased fitness on skin [30]. This repertoire of cell
morphologies demonstrates the plasticity of C. albicans
and its evolution as a human commensal.
Transition to damage-causing pathogen and disease
Commensalism of C. albicans on mucosal surfaces is
thought to occur with yeast cells. In agreement with this,
epithelial cells do not readily recognise the yeast form of
C. albicans [31]. However, under periods of immune
suppression, trauma and dysbiosis, abiotic and biotic cues
induce C. albicans morphogenesis resulting in epithelial
activation and induction of a proinflammatory response
[31]. In vulvovaginal candidiasis (VVC), the vaginal epi-
thelium becomes sensitised to C. albicans, and its activa-
tion results in significant neutrophil recruitment [2]. ThisCurrent Opinion in Microbiology 2017, 40:58–64 hyperactivation of the innate immune system generates a
strong non-protective immune response that drives the
immunopathology associated with VVC [2]. One question
that arises is why do healthy women maintain C. albicans
in a commensal relationship and what is the selective
pressure that promotes persistent colonisation in the
vagina? An answer to this question may lie in the location
of the vagina between the rectum and urethra. The
antagonistic relationships C. albicans exerts on many
bacterial species, including those that cause potentially
life threatening urinary tract infections, (UTIs), might
inhibit migration of these pathogens from the rectum to
the urethra, providing a selective pressure to maintain
C. albicans in the vagina as a mutualistic symbiont. The
primary etiological agent responsible for UTIs is uro-
pathogenic Escherichia coli (>80% cases) [32]. Candida
colonization of the vagina increases in puberty, coinciding
with hormonal changes that promote fungal adherence
and growth [33]. Prepubescent girls also have the highest
occurrence of Gram-negative bacteria in the vagina
(mainly E. coli), while the highest occurrence of Candida
species is in women of child-bearing age [34]. This
suggests that Candida inhibits E. coli in the vaginal
environment either directly, or via colonization resis-
tance, providing a microbiological barrier between the
anus and urethra.
Asymptomatic oral carriage of Candida in the oral cavity is
mediated via non-specific host barriers (saliva, antimicro-
bial peptides, among others) and strong immune defences.
However, the onset of AIDS or use of cancer chemotherapy
results in oropharyngeal candidiasis (OPC). The role of host
factors in the predisposition to OPC is discussed below.
Entry of C. albicans into the bloodstream, via implanted
medial devices, translocation from the gut during abdom-
inal surgery or neutropenia, results in systemic infection.
Key target organs include the kidney, spleen and liver,
where C. albicans exerts excessive damage. Device asso-
ciated infections permit the formation of drug and host
resistant biofilms, which continually seed infections if not
removed. Due to the lack of appropriate diagnostics and
non-specific symptoms, infections are often misdiagnosed
resulting in increased mortality rates.
Candidiasis and dysbiosis
Shifts in fungal populations leading to dysbiosis are
associated with various diseases [35,36]. In this situation,
members of the mycobiome transition from commensal to
parasitic symbionts. Whether these shifts are causative or
indicative of disease is likely a sliding scale as host and
symbionts influence each other within the eco-system.
Prolonged administration of antibiotic therapy predis-
poses women to VVC, suggesting that dysbiosis of the
vaginal flora is a prerequisite for symptomatic Candida
colonisation. Initially it was suggested that antibiotic
treatment removed lactobacilli from the vaginal mucosa,www.sciencedirect.com
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formation. In agreement with this, lactobacilli have been
proposed to reduce Candida colonisation [37], and have
been explored as a potential probiotics [38]. However,
other studies suggest that vaginal pH, and the lactobacilli
population are not significantly altered in VVC [39], and
that Candida colonisation is more common in women with
a lactobacillus dominated microflora [40]. Therefore, the
role of this amensalistic relationship warrants further
investigation.
Treatment with oral antifungals perturbs the intestinal
mycobiome, reducing the populations of Candida, whilst
promoting the expansion of Aspergillus, Wallemia and
Epicoccum, and causing increased allergic airway disease
[41]. On the other hand, the use of oral antibiotics,
depleted the bacterial composition of the GI microbiome,
promoting the expansion of Candida [42]. The conse-
quence of Candida overgrowth in the GI tract is still
controversial. However, individuals with high Candida
burdens appear to be more prone to intestinal inflamma-
tory diseases [43], although the role of Candida remains to
be determined.
Role of the host: genetic mutations
Genetic susceptibility to C. albicans infections varies
according to site of infection, and not all infections are
associated with genetic mutation. Systemic infection is
associated with defects in innate immunity (neutrophil
function) while oropharyngeal candidiasis (OPC) is asso-
ciated with defects in cellular immunity (primarily CD4+
T cells). A major focus of recent genetic linkage studies is
chronic mucocutaneous candidiasis (CMC), which is an
infectious phenotype in patients with inherited or
acquired T cell deficiency (primarily IL-17 immunity).
CMC is an extremely rare familial disorder, with a current
worldwide cohort <300 patients, and is characterized by
chronic infection of skin, nails, and oral/genital mucosa
[44]. Defects in STAT1 result in CMC due to defects in
IL-17, IFN-g and IL-22 signalling [45]. IL-17 signalling is
essential for controlling oral carriage of Candida, with
defects in many of the signalling components resulting
in OPC [46]. OPC can also result from an autoimmune
disease where the patient generates antibodies to IL-17A,
IL-17F and IL-22 [47].
Genetic predisposition to VVC is still an emerging topic.
One study found higher frequencies in mutations associ-
ated with increased expression of mediators involved in
mucosal tolerance (IL-22 and IDO1) in controls versus
RVVC patients [48]. This study also found higher fre-
quencies of a mutation causing a premature stop codon in
the C-type lectin receptor Dectin-1 in women with
RVVC, which mediates IL-22 production [48]. Polymor-
phisms in mannose binding lectin (MBL), a component of
innate immunity that triggers complement activation, are
also found at higher frequencies in RVVC patients and arewww.sciencedirect.com associated with leading reduced vaginal MBL levels
[49,50]. Overall, these studies support the concept that
pathways important in mucosal tolerance that may limit
innate responsiveness to a commensal symbiont, promote
resistance to RVVC.
Fungal factors
The most studied and important virulence attribute of
C. albicans is its ability to reversibly switch morphologies,
between yeast, pseudohyphal and true hyphal growth.
Temperature, CO2, pH, serum, quorum sensing mole-
cules, nutrient availability and hypoxia all regulate mor-
phogenesis [51]. As outlined above, each of these
morphologies play distinct roles in colonisation and para-
sitism, and inhibition of morphogenesis dramatically inhi-
bits fungal virulence. Other important virulence factors
include the expression of adhesins (i.e. ALS family) and
cell wall proteins (i.e. Hwp1) that enable attachment to
host cells [52]. The Als5 adhesin is expressed during
commensal growth, but repressed during pathogenicity.
In agreement with Als5 playing a role in fungal commen-
salism, expression of C. albicans Als5 in S. cerevisiae
promotes colonisation of the nematode gastrointestinal
tract, without affecting survival [53]. Therefore, Als5 may
be a critical factor for C. albicans commensalism. Once
attached, C. albicans can actively penetrate mucosal bar-
riers. The expression of SAPs is thought to be essential to
this process, degrading proteins on host cells, and dis-
rupting the host’s protective barriers (i.e. degradation of
mucin) [54]. Due to the role of SAPs in epithelial damage
SAP expression is correlated with virulence rather and
commensalism [29]. Finally, C. albicans induces epithelial
damage through the secretion of candidalysin, a novel
pore forming peptide. Candidalysin is predominately
expressed by hyphal cells and is responsible for the
majority of host damage exerted by C. albicans [55].
The role of candidalysin in commensalism has not been
extensively studied, but deletion of candidalysin does
reduce colonisation levels in murine models of OPC
[55] suggesting that candidalysin may play roles in
commensalism as well as pathogenesis. In addition to
this repertoire of fungal virulence factors, C. albicans can
also modulate the structure of its cell wall to either
conceal or reveal immune stimulatory PAMPs on its
surface [56,57,58]. This pliability of the cell wall archi-
tecture enables C. albicans to control the innate immune
response. Therefore, C. albicans has uniquely positioned
itself as a commensal symbiont, with a plethora of ways to
sense and respond to changes within the host that ensure
successful transition from commensalism to parasitism
and initiation of disease during periods of weakened host
defences.
Conclusion
Fungi form an important part of our microbiome, with
symbiotic relationships ranging from commensal to para-
sitic. The symbiotic relationship between humans andCurrent Opinion in Microbiology 2017, 40:58–64
62 Host-microbe interactions: fungifungi is greatly underappreciated and under researched.
Given that many fungi are opportunistic pathogens,
understanding the balance and transitions between these
relationships is vital for the future of medial mycology.
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